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Abstract
Background: The expression of pregnancy-associated plasma protein A (PAPP-A) was identified by
immunohistochemistry (IHC) in culprit atherothrombotic plaque specimens harvested from patients admitted with
ST-segment elevation myocardial infarction (STEMI).
Methods: The atherothrombotic samples were collected from a consecutive cohort consisting of 20 individuals
admitted with STEMI to Stavanger University Hospital, Norway, from 2005-2006, presenting angiographically with
an acute thrombotic occlusion of a coronary artery characterized by TIMI flow 0. The atherothrombotic plaques
were obtained by aspiration thrombectomy during percutaneous coronary intervention within 12 hours from the
onset of symptoms and prepared for IHC analysis.
Results: In the IHC analysis staining for PAPP-A occurred in the extracellular matrix of the plaques and no evidence
of staining for PAPP-A was found in the thrombi.
Conclusion: Our results indicate that in vivo PAPP-A is strongly expressed in atherothrombotic plaques harvested
from patients admitted with STEMI, as documented by IHC.
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Background
Pregnancy-associated plasma protein A (PAPP-A) is a
zinc-binding matrix metalloproteinase that can be
detected in the blood of patients with acute coronary
syndromes (ACS) [1,2]. There is histological evidence,
using specific monoclonal antibodies, that PAPP-A is
abundantly expressed in both eroded and ruptured cor-
onary plaques, but not in stable plaques, in patients who
have died suddenly of cardiac causes. Furthermore,
accumulating evidence suggests that PAPP-A may play a
pivotal role in the development of atherosclerosis and
subsequent plaque instability in ACS patients [1].
In a prior study we have assessed the immediate effects
of coronary reperfusion procedures on the plasma concen-
trations of PAPP-A in patients admitted with ACS and
ST-elevation myocardial infarction (STEMI) [3]. However,
existing data does not allow us to define the exact role of
PAPP-A in plaque disruption. Although, this metallopro-
teinase has been shown in earlier studies to be expressed
in ruptured plaques, these results were limited by the fact
that the histological samples were collected postmortem
[1]. Therefore, we wanted to identify the expression of
PAPP-A by immunohistochemistry (IHC) in culprit
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atherothrombotic plaque specimens harvested from
patients admitted with STEMI.
Methods
The atherothrombotic plaques, consisting of a mixture of
unstable plaques and intra-coronary occlusive and mural
thrombi, were obtained by aspiration thrombectomy dur-
ing percutaneous coronary intervention (PCI) from 20
subjects admitted with STEMI. These patients received
5.000-7.500 IU of unfractionated heparin during the pro-
cedure. The subjects belonged to a consecutive cohort
admitted within 125 (30-720) minutes [median (range)]
from the onset of symptoms to Stavanger University
Hospital, Norway, from 2005-2006. They presented
angiographically with an acute thrombotic occlusion of a
coronary artery characterized by TIMI flow 0. The ather-
othrombotic specimens with plaque fragments were col-
lected during the PCI procedure and immediately placed
into a tissue fixative consisting of formalin.
The formalin treated samples were first stored one
hour in 70% ethanol, and then embedded in paraffin.
Briefly, 4-μm-thick sections from the paraffin blocks
were air-dried on superfrost slides, and then frozen until
use. Sections from all the blocks were stained with hae-
matoxylin and eosin for general orientation and identifi-
cation of tissues and structures. The slides for IHC were
deparaffinised with toluene, rehydrated in ethanol,
boiled in 10 mM Citratebuffer pH 6.0 and TBS-0.025%
Tweenbuffer pH 7.6, and incubated with the primary
antibody; the polyclonal rabbit anti-human Pregnancy
Associated Plasma Protein A: Ig fraction (A0230 Dako),
Denmark. For IHC detection and visualisation we used
the DakoCytomation EnVision+ System HRP, Rabbit
K4010, Dako, Denmark. Furthermore, histological speci-
mens from surgically removed human placenta tissue
were used as positive controls (Figure 1).
Results
Seven samples were not suitable for evaluation because of
technical reasons mainly due to insufficient material col-
lected at the site of coronary occlusion. In three of the 13
remaining samples, plaque components were character-
ized by necrotic material with remnants of cholesterol-
crystals (Figure 2). Inhomogeneously structured con-
glomerates of proteinaceous material containing fibrin,
platelets, erythrocytes, and scattered white blood cells,
were consistent with a thrombus (Figure 3). PAPP-A
expression was demonstrated in the extracellular matrix
of the plaques as illustrated by figure 2. There was no
staining for PAPP-A in the thrombi (Figure 3).
Discussion
Our results suggest a relation between ACS and the
expression of PAPP-A in atherothrombotic plaques.
This finding is in accordance with the study conducted
by Bayes-Genis and colleagues [1], whereas, immunohis-
tochemical analysis by Rossen et al. [4] failed to identify
PAPP-A in atherosclerotic plaques from ACS patients.
The discrepancies reported may be explained by the dif-
ference in the molecular nature of PAPP-A originating
from placenta as compared to arterial atheromatous pla-
ques. Thus, some assays developed for the placental
form may also react against the plaque-associated form,
whereas others will not, depending on the nature of the
antibodies in the test systems [5]. Furthermore, it has
been shown that heparin effectively competes for the
binding site of PAPP-A on cell surfaces [6]. In addition,
results from an interesting animal study documented
that heparin facilitates the detachment of PAPP-A from
the vessel wall [7]. Therefore, heparin administration
during STEMI could explain the lack of PAPP-A
Figure 1 Immunohistochemistry of placental tissue (positive
control). The trophoblastic layer is strongly expressing PAPP-A
(reddish brown staining).
Figure 2 Immunohistochemistry of sampled atherothrombotic
material. Atheromatous area showing diffuse immunoreactivity to
PAPP-A (reddish brown staining). The staining is negative in the
thrombus (white-blue area).
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staining in the thrombi. Despite these controversies, it
cannot be excluded that the plaques may play a role as
a reservoir for PAPP-A release following PCI [3]. How-
ever, the exact mechanistic role of this marker needs to
be clarified.
Conclusion
Our results indicate that in vivo PAPP-A is strongly
expressed in atherothrombotic plaques harvested from
patients admitted with STEMI, as documented by IHC.
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Figure 3 Sampled thrombus without atheromatous material
from the plaque. Immunohistochemistry of proteinaceous material
containing fibrin, platelets, erythrocytes and white blood cells
without PAPP-A expression.
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